HUAWEI DESIGN
833427
HST
870726
Hangzhou Huasu Technology
301157
Suzhou Alton Electrical & Mechanical Industry
301187
Shanghai Kaytune Industrial
301001
CN Stock MarketDetailed Quotes
002004 Huapont Life Sciences
- 4.35
- -0.04-0.91%
Market Closed Jan 8 15:00 CST
8.61BMarket Cap34.52P/E (TTM)
4.43High4.29Low178.19KlotVolume4.42Open4.39Pre Close77.56MTurnover0.95%Turnover Ratio28.43P/E (Static)1.98BShares5.2352wk High0.85P/B8.19BFloat Cap3.5652wk Low4.83Limit Up1.88BShs Float18.17Historical High3.95Limit Down3.19%Amplitude-1.63Historical Low0.22Dividend TTM4.35Avg Price104.02KlotAsk5.06%Div YieldTTM100Lot Size71.69KlotBid
Huapont Life Sciences News
Express News | Kaisheng New Materials: The controlling Shareholder plans to issue no more than 1 billion yuan of exchangeable CSI Enterprise bonds.
Huapont Life Sciences (002004.SZ): Plans to privately issue no more than 1 billion yuan of exchangeable bonds.
Gelonghui, December 10 - huapont life sciences (002004.SZ) announced that the company will hold the 21st meeting of the 8th board of directors on December 10, 2024, to review and approve relevant proposals including "Proposal on the Company's Compliance with Conditions for Private Placement of Exchangeable Corporate Bonds", "Proposal on the Company's Private Placement Plan for Exchangeable Corporate Bonds", and "Proposal to Authorize the Board of Directors to Handle All Matters Related to this Private Placement of Exchangeable Corporate Bonds". Taking into full consideration the company's global strategy and combining the company's actual situation, the company intends to privately place exchangeable bonds to professional institutional investors.
Express News | huapont life sciences: Wholly-owned subsidiary huapont pharmaceutical obtained the pharmaceutical registration certificate for Benidipine hydrochloride tablets.
Express News | Huapont Life Sciences establishes a new technology company with multiple AI businesses.
Huapont Life Sciences (002004.SZ): has repurchased 0.35% of shares accumulated.
On November 1, Eguo.com reports: Huapont Life Sciences (002004.SZ) announced that, as of October 31, 2024, the company has repurchased a total of 6,959,908 shares through centralized trading, accounting for 0.35% of the company's current total share capital. The highest fill price was 4.65 yuan/share, the lowest fill price was 3.84 yuan/share, and the total amount paid was 29.4993 million yuan (excluding trading fees).
Huabang Health: Report for the third quarter of 2024
Huapont Life Sciences (002004.SZ) released its performance for the first three quarters, with a net income of 0.452 billion yuan, a year-on-year decrease of 10.49%.
huapont life sciences (002004.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
huapont life sciences (002004.SZ): net income of 0.452 billion yuan in the first three quarters, a year-on-year decrease of 10.49%.
On October 28th, Huapont Life Sciences (002004.SZ) announced its third quarter report for 2024, with the company achieving revenue of 8.9098 billion yuan in the first three quarters, a year-on-year increase of 0.64%; the net income attributable to shareholders of the listed company was 0.452 billion yuan, a year-on-year decrease of 10.49%; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.436 billion yuan, a year-on-year decrease of 9.78%; and the basic earnings per share was 0.2288 yuan.
Express News | Yingtai Biology: Huapont Life Sciences releases 0.148 billion shares of pledged
Express News | huapont life sciences: Subsidiary Kechi Delong's developed herbicide-resistant cotton KJC017 has obtained the agricultural transgenic biosafety certificate.
huapont life sciences (002004.SZ): has cumulatively repurchased 6.9599 million shares
On September 2, Guolonghui announced that as of August 31, 2024, Huapont Life Sciences (002004.SZ) has repurchased a total of 6,959,908 shares of the company through centralized trading, accounting for 0.35% of the company's current total share capital. The highest fill price was 4.65 yuan/share, the lowest fill price was 3.84 yuan/share, and the total amount paid was 29,499,300 yuan (excluding transaction fees).
Huabang Health: 2024 Semi-Annual Report Summary
Huabang Health: 2024 Semi-Annual Report
huapont life sciences (002004.SZ): the net income in the first half of the year was 0.314 billion yuan, a decrease of 19.02% year-on-year.
Huapont Life Sciences (002004.SZ) announced its semi-annual report for the year 2024, with total revenue of 5.922 billion yuan, a year-on-year increase of 0.91%; net income attributable to shareholders of the listed company was 0.314 billion yuan, a year-on-year decrease of 19.02%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.296 billion yuan, a year-on-year decrease of 21.64%; basic earnings per share was 0.1586 yuan.
Huapont Life Sciences (002004.SZ) released its performance for the first half of the year, with a net income of 0.314 billion yuan, a decrease of 19.02%.
Huapont Life Sciences (002004.SZ) released its 2024 interim report, during the reporting period, the company achieved revenue...
Huapont Life Sciences (002004.SZ): As of August 9, 2024, the company has 79,239 shareholders.
On August 13th, Gelonhui reported that as of August 9th, 2024, the number of shareholders of Huapont Life Sciences (002004.SZ) was 79,239.
Huapont Life Sciences (002004.SZ): Both Purejin and Puxin Biotech are companies in which the company has invested.
On August 9, Guolong News reported that Huapont Life Sciences (002004.SZ) stated on the investor interaction platform that Prigen and Pu new biological are both companies in which the company holds shares. Prigen is mainly engaged in the research and development of innovative drugs for cell and gene therapy. Currently, the company holds a total of 13.19% of its equity through direct and indirect means. Pu new biological is mainly engaged in the CDMO business of cell and gene therapy drugs. Currently, the company holds 8.99% of its equity. If the company plans to further increase its shareholding in the future, it will strictly comply with relevant requirements and promptly fulfill its information disclosure obligations.
Huapont Life Sciences (002004.SZ): has repurchased 0.35% of its shares in total.
On August 1st, Gelunhui reported that Huapont Life Sciences (002004.SZ) accumulated repurchased 6,959,908 shares of the company through centralized trading as of July 31, 2024, accounting for 0.35% of the total share capital. The highest fill price is CNY 4.65/share, the lowest fill price is CNY 3.84/share, and the total amount paid is CNY 29,499,256.13 (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
Huapont Life Sciences (002004.SZ): The specific timetable for Hanjiang Pharmaceutical's listing has not yet been determined.
On July 16th, Huapont Life Sciences (002004.SZ) stated on the investor interaction platform that Hanjiang Pharmaceutical is a wholly-owned subsidiary of the company, mainly engaged in the R&D, production and sales of pharmaceutical APIs and intermediates, covering products such as steroid hormones, anthelmintics, respiratory and digestive system drugs, and has established long-term cooperation with internationally renowned pharmaceutical companies such as Abbott Laboratories, Johnson & Johnson, Eli Lilly and Co., and Merck. The specific timetable for Hanjiang Pharmaceutical's listing has not yet been determined, but Hanjiang Pharmaceutical has the possibility of being listed based on its business and operating performance. Please refer to the company's announcement for specific information.
Huapont Life Sciences (002004.SZ): As of July 10th, the number of shareholders in the company is 79,950.
On July 16th, Gelunhui reported that as of July 10, 2024, the number of shareholders in Huapont Life Sciences (002004.SZ) was 79950.
